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Sclerostin antibody (SclAb) therapy has been suggested as a novel therapeutic approach toward 
addressing the fragility phenotypic of osteogenesis imperfecta (OI).  Observations of cellular and 
transcriptional responses to SclAb in OI have been limited to mouse models of the disorder, leaving a 
paucity of data into the human OI osteoblastic cellular response to the treatment.  Here, we explore 
factors associated with response to SclAb therapy in vitro and in a novel xenograft model using OI bone 
tissue derived from pediatric patients. 
Bone isolates (~2 mm3) from OI patients (OI Type III, Type III/IV and Type IV, n=7; non-OI 
control, n=5) were collected to media, randomly assigned to an untreated (UN), low-dose SclAb (TRL, 
2.5 µg/mL), or high-dose SclAb (TRH, 25 µg/mL) group and maintained in vitro (37°C). Treatment 
occurred on day 2 and 4 and removed on day 5 for TaqMan qPCR analysis of genes related to the Wnt 
pathway. A subset of bone was implanted subcutaneously into an athymic mouse, representing our 
xenograft model, and treated (25 mg/kg s.c. 2x/wk for 2/4wks).  Implanted OI bone was evaluated using 
µCT and histomorphometry. 
Expression of Wnt/Wnt-related targets varied among untreated OI bone isolates. When treated 
with SclAb, OI bone demonstrated an upregulation in osteoblast and osteoblast progenitor markers 
which was heterogeneous across tissue. Interestingly, the greatest magnitude of response generally 
corresponded to samples with low untreated expression of progenitor markers. Conversely, samples with 
high untreated expression of these markers demonstrated a lower response to treatment. In vivo 
implanted OI bone demonstrated a bone forming response to SclAb via µCT and corroborated by 
histomorphometry. SclAb induced downstream Wnt targets WISP1 and TWIST1 and elicited a 
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compensatory response in Wnt inhibitors SOST and DKK1 in OI bone with the greatest magnitude from 
OI cortical bone. 
Understanding patients’ genetic, cellular, and morphological bone phenotypes may play an 
important role in predicting treatment response, thus aiding clinical decision making for 
pharmacological intervention to address fragility in OI.  
 








  Osteogenesis imperfecta (OI) is a rare and severe congenital bone dysplasia characterized by low 
bone mass and poor bone quality with increased pathological fracture risk.[1] OI is both genetically and 
clinically heterogeneous; the bone dysplasia can currently be categorized into 18+ genetically unique 
types ranging in severity from mild forms with minor skeletal clinical manifestations to perinatally 
lethality.[2-4] Further complicating the disease are the different possible modes of inheritance 
(dominant, recessive or X-linked gene mutations) and variability associated with the affected genetic 
loci resulting in the range of phenotypic presentation. [5] Further, patients with the same OI-causing 
mutation can present with different clinical phenotypes. [6] In up to 85% of cases, OI is caused from a 
mutation in the COL1A1 or COL1A2 encoding the α1 or α2 chain of type I collagen respectively, 
resulting in an underproduction of normal collagen or secretion of defective collagen chains depending 
on the mutation.[7-9] More recently, other proteins localized in the matrix, endoplasmic reticulum (ER), 
ER-golgi, and nucleus have been identified in the pathogenesis of OI and make up the remaining 15% of 
cases.[3, 9-20]  This spectrum of genotype-phenotype variability has made both diagnosis and 
management of the disease challenging; as such, no cure for OI exists, there is no United States Food 
and Drug Administration or European Medicines Agency approved pharmacological treatment and 
consensus on an appropriate treatment strategy has yet to be identified. [21, 22] 
  Pharmacologic treatment strategies for OI have evolved from approaches developed to treat 
osteoporosis, a metabolic bone disease. These strategies aimed at eliciting an increase in bone mass, an 
improvement in architecture and a decrease in fracture risk, often result in a variable clinical response 
when applied to OI. Current clinical pharmacological approaches to manage OI relies on anti-resorptive 
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bisphosphonates, yet bisphosphonates have demonstrated variable patient outcomes depending on OI 
phenotype, severity and bone site.[23, 24] Further, long-term bisphosphonate use in pediatric OI is a 
concern due to its suppression of bone turnover and the drug’s long half-life which leads to long-term 
residence in the bone. [25]  Inconsistent clinical pediatric OI results have also been reported with 
Denosumab, a RANKL inhibitor, and concerns regarding hypercalciuria development during active 
therapy observed in pre-clinical studies have limited its clinical use. [26-28] More recently, bone-
forming sclerostin antibody (SclAb) has emerged as a promising alternative or adjuvant to existing 
therapies and acts by inhibiting sclerostin, a negative regulator of bone formation. {Li, 2014 #58} SclAb 
has elicited significant increases in bone mineral density (BMD) and quality during clinical trials for 
post-menopausal osteoporosis [29, 30] and stimulated markers of bone formation, reduced resorption 
and increased lumbar spinal areal BMD in adults with moderate OI (limited to type I, III, or IV). [31]  
  Despite these findings, effects in the pediatric OI population and across all OI types remain 
unknown. Different OI phenotypes appear to respond differently to therapies. Pre-clinically, the bone-
forming response to SclAb has varied in magnitude from strong in the moderate knock-in Brtl/+ murine 
model, moderate in the recessive severe Crtap/-/- murine model, and a lower bone-forming response in 
the dominant severe Col1a1 jrt/+ murine model.[32-36] Therefore, factors that contribute to the 
heterogeneity of the disorder, including skeletal morphology and untreated gene expression profile may 
play an important role in the patient’s response to therapy. 
  Understanding the transcriptional response to treatment in the diseased target tissue is of great 
interest. Gene expression response following SclAb treatment has been reported in rat models of post-
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menopausal osteoporosis and in female Balb/c mice, [37-40] highlighting the unique signaling events 
and compensatory response occurring in the osteoblast lineage as a result of SclAb. However, patterns 
of gene expression response due to treatment in human OI bone tissue remains unknown and difficult to 
assess clinically. We sought to evaluate gene expression profiles in native pediatric OI bone tissue and 
describe the acute gene expression response to SclAb treatment across OI patients with severe and 
moderate phenotypes at a variety of anatomic sites and bone types. We explore how the samples’ 
untreated cellular condition and baseline morphological phenotype contribute to treatment response 
during acute sclerostin inhibition. 
 
Materials and Methods 
Study Design 
  Seven pediatric OI patients undergoing corrective surgical orthopaedic intervention were 
prospectively enrolled and the subject and/or legal guardian provided informed consent for this 
Institutional Review Board approved study. Five additional age-matched pediatric non-OI deidentified 
patients undergoing anterior cruciate ligament (ACL) reconstruction as a result of sport-related injury 
were recruited and tissue was considered exempt by the Institutional Review Board. Detailed subject 
demographics including OI type and bone harvest location can be appreciated in Table 1. Native bone 
typically discarded as surgical waste was collected immediately to media (αMEM/10% fetal bovine 
serum (FBS)) and placed on ice for experimental preparation.  Bone tissue was divided into a Falcon 12-
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well microplate (Corning Inc., Corning, New York) with each well containing 3 mL of media and 
maintained in culture at 37°C. Each well contained one solid bone isolate ~2 mm3 in size and each donor 
yielded up to 14 usable bone isolates (Table 1). Bone was randomly assigned to an untreated (UN), 
treated with a low dose of SclAb (TRL, 2.5 µg/mL), or treated with a high dose of SclAb (TRH, 25 
µg/mL) condition. Each donor had enough bone tissue to repeat each UN, TRL, TRH condition 2-4 
times. Wells containing tissue and media were dosed directly with SclAb on days two and four and all 
samples were removed on day five to 1 mL of TRIzol reagent (Invitrogen, Carlsbad, CA) and kept at -
80°C until RNA isolation occurred. For all conditions, media was changed on day two and four prior to 
treatment. One bone sample from each donor was fixed immediately in 10% neutral buffered formalin 
(NBF) for 24 hours, decalcified in 10% ethylenediaminetetracetic acid (EDTA) for 15-20 days, paraffin 
processed and stained with hematoxylin and eosin (H&E) to determine bone morphology using 
established procedures.[41]. A detailed schematic can be found in Figure 1A. 
Due to the amount of donor bone tissue procured, a subset of bone tissue from patients OI3, OI4 
and OI6 were collected to media and immediately implanted subcutaneously on the dorsal surface of an 
athymic mouse (Foxnnu [002019]; The Jackson Laboratory, Bar Harbor, ME, USA) representing our 
xenograft model to evaluate the effects of SclAb in a host-derived system more closely recapitulating 
the in vivo microenvironment (Figure 1B) using the methods described in detail in Surowiec et al. [42] 
In short, fourteen bone samples in total were implanted and mice were randomly assigned to an 
untreated or SclAb treated group. SclAb treatment (25 mg/kg) was administered to the host (mouse) 
subcutaneously two times a week for either 2 or 4 weeks where the mice were euthanized by CO2 
inhalation followed by bilateral pnuemorthorax. All mice received calcein (30 mg/kg, intraperitoneal 
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(i.p.) injection), administered seven days before sacrifice and alizarin (30 mg/kg, i.p.) administered one 
day prior to sacrifice, to follow new bone formation. Implanted mice underwent µCT imaging (Bruker 
Skyscan 1176, Bruker BioSpin, Belgium) 24 hours following implantation and immediately following 
euthanasia using an X-ray voltage of 50 kV, 800 µA current and a 0.5 mm aluminum filter. Scans were 
reconstructed at an 18 μm isotropic voxel size and calibrated with the use of two manufacturer provided 
hydroxyapatite standards. The bone implant was manually segmented followed by a series of automated 
processes so that only implant was extracted and analyzed for longitudinal changes (presented as a 
percent change from pre- to post- scans) in bone surface (CTAn Version 1.15.4.0, Bruker Biospin, 
Belgium). Following imaging, OI bone tissue implants were removed from the host and plastic 
processed for histomorphometric analysis using standard laboratory procedure. All experimental animal 
procedures were approved by the University of Michigan Committee for the Use and Care of Animals.  
 
Bone tissue preparation and RNA extraction  
  Total RNA was extracted from each bone isolate by first pulverizing each bone in 1 mL TRIzol 
using a high-speed tissue homogenizer (Model 1000; ThermoFisher Scientific). Each bone isolate 
underwent three 20-second cycles of homogenization and was placed on ice between cycles. The bone’s 
total nucleic acid content was isolated using 0.2 mL of 24:1 chloroform:isoamyl alcohol per 1 mL of 
TRIzol, centrifuged at 12000 g for 15 minutes at 4°C where the supernatant containing the RNA fraction 
was removed by pipetting. RNA was then purified using the RNeasy Mini Kit (Qiagen, Valencia, 
California) followed by DNA digestion with an RNase-Free DNase Set (Qiagen) following instructions 
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supplied by the manufacturer. Finally, total RNA was eluted in 30 µL of RNase-free water. For quality 
control, RNA concentration extracted from each bone isolate was determined using NanoDrop 2000 
(ThermoFisher Scientific) followed by assessment of RNA quality using a bioanalyzer (Model 2100, 
Pico Kit; Agilent Technologies, Santa Clara, California) to generate an RNA integrity number (RIN). In 
order to maximize nucleic acid content from each patient condition, RNA from each well condition 
(UN, TRL, TRH) per patient with an RNA integrity number (RIN) of 5.5 or greater were pooled to yield 
200 ng per condition and a new concentration value was determined using the NanoDrop. The RIN 
number of 5.5 was chosen due to the rarity of the human tissue and few samples did not meet this 
threshold; two non-OI and four OI bone samples had RIN values below 5.5 and were excluded from 
analysis and not pooled as they did not meet our quality standard for the study. The average RIN number 
was 8.8; pooled non-OI bone RIN values ranged from 6.3-10 and OI patient bone from 6.7-9.9. 
Extracted RNA was stored at -80°C until further processing. 
TaqMan qPCR analysis 
  The expression levels of 10 genes related to the canonical and non-canonical Wnt signaling 
pathway and one endogenous control were quantified using TaqMan quantitative real-time polymerase 
chain reaction (RT-qPCR) (Table 2). Specifically, downstream Wnt targets (WISP1, TWIST1), 
inhibitory regulators of bone formation (SOST, DKK1), markers of osteoblastogenesis (SP7, RUNX2), 
osteoblast markers (BGLAP, COL1A1), and markers of osteoclast differentiation and activity (OPG, 
RANKL) were evaluated. The panel represents a subset of markers in the bone remodeling cycle many of 
which have been identified as key targets for SclAb therapy in prior animal studies.[37-39, 43] Due to 
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the rarity of the OI bone tissue and the size of the available harvested bone (which affected the amount 
of total nucleic acid we were able to extract), we chose to analyze only one housekeeping gene 
(HPRT1), which has been documented in the literature as a stable gene across experimental conditions in 
human bone studies. [44, 45]   
  Pooled, purified RNA samples underwent reverse transcription using qScript cDNA SuperMix 
(Quanta Biosciences, Gaithersburg, MD) using 1.5 µg of retro-transcribed RNA per reaction followed 
by thermocycling (C1000 Thermal Cycler, Bio-Rad Laboratories, Hercules, California) according to 
manufacturer recommendations. TaqMan Gene Expression Master Mix (Applied Biosystems) was 
combined with cDNA and validated TaqMan primer (Applied Biosystems, Foster City, California) and 
loaded into a 96-well microfluidic array card (Applied Biosystems, Foster City, California). Each array 
card permitted for two patients’ (one OI, one non-OI) samples (UN, TRL, TRH, each) and five primers 
plus the housekeeping primer simultaneously with twelve array cards in total evaluated. All reactions 
were run in duplicate and a no-template control and no-reverse transcription control were utilized. Array 
cards were centrifuged at 4°C (Legend XTR (with custom TaqMan array card bucket); Sorvall, 
Waltham, Massachusetts), sealed and ran in accordance to recommendations from the manufacturer. 
  Amplification plots were generated and expression of SOST, DKK1, COL1A1, BGLAP, OPG, 
RANKL, RUNX2, TWIST1, WISP1, and the housekeeping gene (HPRT1) were quantified. Baseline and 
threshold settings were adjusted to obtain an accurate threshold cycle (CT) that was standard across all 
patients (OI 1-7 and non-OI 1-5) and conditions (UN, TRL, TRH) per each individual gene of interest in 
order to understand baseline cellular expression levels of the donor tissue and treatment response to 
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SclAb. Comparative CT method (ΔΔCT) was used to calculate fold change expression levels by 
normalizing data to endogenous HPRT1 by averaging the duplicates of the gene of interest and the 
duplicate of the housekeeping gene for each patient per condition.[46] Experiments in which duplicate 
reactions deviated by four or more cycles (CT) were deemed a failed reaction due to technical error and 
thus excluded. 
  The individual OI patient UN condition was normalized to the average non-OI UN condition 
(control) to quantify variability in untreated OI gene expression and to provide a snapshot of  genotypic 
variability present among the cohort of harvested OI patient samples irrespective of OI clinical 
phenotype. We then quantified the individual patient response to SclAb by normalizing each individual 
patient sample’s treatment condition (TRL, TRH) to that patient sample’s untreated condition to assess 
treatment response variation among individual patient tissue. Next, we evaluated the response to SclAb 
by clinical phenotype by averaging the treatment condition (TRL, TRH) normalized to the average 
untreated condition within each OI type (Type III, Type III/IV, Type IV). Finally we normalized each 
mean treatment condition (TRL, TRH) within OI type to the mean untreated non-OI control allowing 
observations on whether SclAb treatment returned gene expression to non-OI untreated control levels.  
Statistical Analysis 
All data were analyzed using GraphPad Prism v7 (GraphPad Software, La Jolla, California). 
Gene expression results are shown as mean ± standard error of the mean (SEM). Differences in 
individual OI untreated gene expression, individual OI treatment response and mean treatment response 
within OI type were statistically evaluated via a paired t-test using the respective ΔCT values as 
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described in detail by Yuan et al. [47] A two-way ANOVA (non-repeated measures) with patient type 
(OI Type III, OI Type III/IV, OI Type IV or Non-OI) and treatment (UN, TRL, TRH) as factors was 
used to determine differences in treatment response to SclAb by patient group. Follow-up Dunnett’s 
post-hoc analysis was used where appropriate in order to compare average OI patient condition 
outcomes back to the average non-OI untreated controls. TaqMan probes have validated amplification 
specificity, sensitivity and efficiency; as such fold changes from the TaqMan assays (up or down) of 1.5 
or greater that were identified as being statistically significant (p < 0.05) via paired t-test or two-way 
ANOVA met our criteria for denoting differences in gene expression levels. [48]  
Results 
  Bone samples harvested from OI patients were of cortical and trabecular origin, while harvested 
non-OI bone originating from metaphyseal tibial tunnel samples during anterior cruciate ligament (ACL) 
reconstruction were morselized trabecular bone pieces approximately 1-2 mm3 (Figure 2). Donor-
derived bone yield varied, ranging from 5-14 usable samples; subjects with lower sample yield 
ultimately resulted in lower nucleic acid concentration which did not allow the evaluation of all 
conditions and/or all genes of interest. For these samples, an abbreviated panel of genes were evaluated 
or the TRL condition was omitted. When a gene or condition was omitted, missing fold-change values 
were denoted herein by “insufficient nucleic acid content” in the figures where appropriate. 
Untreated Gene Expression was Heterogeneous among OI Patients 
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Untreated expression levels for all ten genes in each individual OI donor normalized to the 
average untreated non-OI control condition was conducted to understand genotypic variability among OI 
subjects. Untreated expression varied among the OI donors regardless of bone morphological or Sillence 
type Figure 3. OI bone generally demonstrated lower expression of downstream Wnt targets (WISP1, 
TWIST1). Inhibitory regulators (SOST and DKK1) were variable between OI. SOST expression for OI1 
was significantly greater compared to non-OI controls (+5.54 fold difference). Osteoblast marker genes 
(SP7, RUNX2) and osteoblast progenitor marker genes (BLGAP, COL1A1) were heterogeneous among 
OI donors and were generally expressed below non-OI levels with some exceptions. OI5 (Type III/IV 
OI) demonstrated both high levels of inhibitory regulator DKK1 and osteoclast precursor RANKL and 
high expression levels of osteoblast and progenitor (SP7, BGLAP) markers well above both non-OI 
controls and OI patients.     
Individual OI donor response to SclAb varied in magnitude  
Individual donor response to SclAb was evaluated using a low and high dose to understand 
response variability among donors. Differences in treatment response among OI donors can be 
appreciated in Figure 4 where significance within each donor between conditions (UN, TRL, TRH) is 
denoted by stars and brackets. A bone-forming response to treatment observed by an upregulation of 
osteoblast activity was observed in nearly all OI samples regardless of bone type (trabecular, cortical) or 
OI Type (III, III/IV, IV). For SP7, treatment response was improved (through a greater upregulation) 
using the TRH dose compared to the TRL. For RUNX2, BGLAP and COL1A1, a dose dependent effect 
was less pronounced among OI donors in these osteoblast-related genes. SclAb induced an upregulation 
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in downstream Wnt targets (WISP1, TWIST1) and an upregulation (compensatory response) in inhibitory 
regulators (SOST, DKK1). The greatest magnitude of upregulation was observed in treated OI cortical-
derived bone tissue (OI2, OI3, OI6) for these targets.  
Response to treatment appeared related to untreated gene expression levels 
Untreated gene expression from each sample appears to influence the magnitude of response to 
SclAb treatment, specifically for osteoblast and osteoblast progenitor genes COL1A1, RUNX2, SP7 and 
BGLAP (Figure 5). Data suggests that samples with the highest untreated osteoblast expression were 
least responsive to the acute SclAb treatment. This can be appreciated in the case of OI2 with high 
untreated expression of SP7 (Figure 3) and down regulation (TRL) and nominal upregulation (TRH) 
with SclAb treatment (Figure 4). A similar observation was made in OI5 for BGLAP and OI1 for 
RUNX2 and COL1A1 genes (Figure 3 and Figure 4). In contrast, samples with low untreated osteoblast 
expression were the most responsive in bone formation markers to SclAb treatment (Figure 5). This can 
be appreciated in OI3, OI6 and OI7 which had the lowest untreated expression of SP7 (Figure 3) and 
the greatest magnitude of upregulation with SclAb treatment (Figure 4). This observation was true 
regardless of dose for OI3 and OI6 and for low dose (TRL) for OI7. Similar observations were made for 
OI7 for genes RUNX2, BGLAP, COL1A1 and for OI5 for RUNX2 and COL1A1 (Figure 3 and Figure 
5). Further, individual samples with low untreated expression of downstream Wnt target TWIST1 and 
inhibitory regulators DKK1 and SOST relative to the untreated average non-OI controls demonstrated 
the largest magnitude of upregulation following SclAb treatment. The increased compensatory response 
of inhibitory regulators DKK1 (OI3 and OI6) and SOST (OI6) with treatment in these samples correlated 
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with low untreated expression of these targets (untreated expression Figure 3, treatment response 
Figure 4). Conversely, high untreated expression for DKK1 in OI5 and SOST for OI1 demonstrated a 
moderate-to-low treatment response with SclAb (Figure 3 and Figure 4) compared to other OI samples 
with more moderate-to-low untreated  
Response to SclAb was also differential by patient’s clinical Sillence type classification  
To determine whether Sillence classification could predict SclAb response, mean SclAb 
treatment response was stratified by the patient’s clinical Sillence classification by averaging the gene 
expression data from OI Type III, OI Type III/IV and OI Type IV patients, respectively (Supplemental 
Figure 1). Gene expression response to SclAb was heterogeneous among clinical OI phenotypes. OI 
Type III samples demonstrated a greater upregulation in TWIST1, BGLAP and RUNX2 with treatment 
while OI Type III/IV had a greater magnitude of upregulation for WISP1, SOST and COL1A1. OI Type 
IV samples demonstrated the greatest upregulation in DKK1, SP7 and a comparable response in BGLAP 
for OI Type III patients. There was no statistical significance reached in gene expression response within 
OI type. 
  Results from two-way ANOVA (non-repeated measures) and follow-up Dunnett’s post-hoc 
testing for each gene of interest comparing average treatment condition (UN, TRL, TRH) within OI type 
(Type III, Type IV, or Non-OI) normalized to average non-OI untreated condition can be appreciated in 
Supplemental Figure 2A-B. Results revealed a significant effect of OI type for downstream Wnt target 
TWIST1, inhibitory regulators SOST and DKK1 and osteoblastogenesis marker RUNX2. Additionally, a 
significant effect of treatment and a significant interaction between treatment and OI type was observed 
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for SOST (Supplemental Figure 2A). OI Type III samples were the only sample conditions which 
differed significantly from the non-OI untreated controls following SclAb treatment (Supplemental 
Figure 2B). Specifically, following treatment OI Type III samples had a significantly greater 
upregulation in TWIST1 (TRL and TRH), SOST, (TRL and TRH), and DKK1 (TRL) above non-OI 
untreated control levels. Following acute SclAb treatment, osteoblast and osteoblast precursor markers 
of SP7, RUNX2, BGLAP and COL1A1 were upregulated to- or above non-OI untreated control levels in 
OI type III samples.    
In vivo treatment confirmed a bone forming response to SclAb 
The subset of OI bone samples from OI3, OI4 and OI6 implanted into our xenograft model 
demonstrated increases in µCT measures of percent change bone surface (BS) following SclAb 
treatment at 2 (OI3, OI4, OI6) and 4 weeks (OI4) (Figure 6A). Two week treated implants demonstrated 
the most robust increase in bone surface (+ 29%) followed by four weeks of treatment which increased 
on average by +12%. Untreated implants demonstrated a mean -3% decrease in BS following the 
implantation duration at two weeks and a slight increase (+10%) following untreated implantation at 
four weeks. Histomorphometry corroborated µCT findings. Implants following two and four weeks of 
treatment demonstrated robust calcein and alizarin fluorochrome labeling compared to the untreated 
implants which had minimal non-specific calcein labeling only (Figure 6B).  




  In this study we explored the impact of SclAb on OI bone cells within their native extracellular 
environment using a panel of 10 key Wnt-related bone targets. Gene expression was heterogeneous 
across untreated conditions both between and within the patient’s phenotypic clinical classification. 
Acute SclAb treatment induced upregulation of osteoblast activity in nearly all OI samples regardless of 
bone origin (trabecular, cortical) or OI Type (III, III/IV, or IV) and response varied in magnitude across 
subject samples. When the average condition response by OI type was normalized to the average non-OI 
untreated controls, SclAb upregulated osteoblast marker and progenitor genes in OI Type III subjects to- 
or above non-OI untreated control levels. Acute inhibition of sclerostin induced an upregulation of 
inhibitory regulators (SOST, DKK1) similar to prior reports in animal models treated with SclAb. The 
sample’s untreated gene expression appeared to influence the magnitude of response to SclAb treatment, 
specifically for osteoblast and osteoblast progenitor genes COL1A1, RUNX2, SP7 and BGLAP. We 
observed that OI bone samples with low untreated expression of a gene targeted by SclAb generally 
demonstrated a greater magnitude of response (upregulation) with treatment. Conversely, samples with 
higher untreated gene expression elicited moderate to minimal upregulation with sclerostin inhibition. 
Gene expression at the time of treatment may provide new insights in predicting treatment response and 
guide clinical decision making in OI.  Due to the rarity of the tissue, we were unable to attribute whether 
the variability in baseline conditions is attributed to anatomic site, bone type, OI subject type, sex, or 
age. 
  Our findings in human pediatric OI tissue share similarities with studies monitoring gene 
expression treatment response to SclAb in animal models of bone loss. Nioi et al. evaluated expression 
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changes in 84 confirmed canonical Wnt target genes in OVX rats treated with SclAb and reported 
significant upregulation in a focused set of Wnt targets: Wisp1, Twist1, Bglap, Gja1 and Mmp2. The 
authors reported the most consistent SclAb treatment response was observed in the Wisp/Twist cluster. 
[39] In our patient tissue, SclAb induced an upregulation of WISP1 and TWIST1.with the greatest 
upregulation in samples with low untreated expression in the WISP/TWIST cluster. WISP1 and TWIST1 
hold important roles in modulating osteogenesis and cell function. WISP1 has been described to act as a 
negative regulator of osteoclastogenesis and its upregulation following SclAb treatment may point to its 
proposed anti-resorptive effects. [49] While TWIST1’s function is not as well defined, the gene is 
thought to serve as a negative regulator of RUNX2 and an upregulation in TWIST1 is suggestive of 
RUNX2 inhibition (a marker of bone formation).[50] Supporting TWIST1’s proposed role, OI1 
demonstrated a large upregulation in TWIST1 and a concurrent downregulation of RUNX2 with 
treatment (Figure 4). It has additionally been proposed that TWIST1 may be responsible for the 
inhibition of osteoblast apoptosis by suppressing TNF-α but TNF-α was not quantified in the present 
study. [51]  
  SclAb stimulates a rapid increase in bone formation in preclinical models [33, 34, 52, 53] and 
increases markers of bone formation, increases BMD, [54] decreases vertebral fracture risk [30] and 
increases trabecular and cortical bone mass [56] in patients with low bone mass. Nioi et al. observed that 
Bglap and Col1a1 were significantly upregulated in osteoblast lineage cells following one dose of SclAb 
in an OVX rat model indicating a bone forming response can be both acute and robust. [39] Our findings 
are supportive of Nioi et al. and others where we observed that SclAb treatment elicited an early bone-
forming response through upregulation of COL1A1 and BGLAP in nearly all treated OI samples. [39, 43, 
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57] This upregulation following short-term treatment reflects initial stages of bone anabolism consistent 
with an eventual increase in osteoblast differentiation. Taken together with WISP1 upregulation,  results 
suggest an increase in bone forming activity and evidence of a concurrent decrease in resorptive activity. 
We observed an upregulation in RANKL (albeit slight) and down regulation in OPG which  align with 
Stolina et al. where no changes in Rankl or Opg were observed following SclAb treatment in aged OVX 
rats. [40] However, Stolina et al. evaluated Rankl and Opg expression following long-term treatment, 
not short-term as in the present study, where treatment-induced bone forming gains may have begun to 
attenuate as previously described. [52, 58, 59] Alternatively, it is possible that the inconsistent results in 
our in vitro model compared to animal models treated with SclAb may be due in part to the unloaded 
condition experienced during culture which may have led to RANKL upregulation.[60] We 
acknowledge, however, that the OI condition may also mirror disuse. Future studies could evaluate the 
in vitro treatment response in human OI tissue under in vitro loading conditions in order to induce 
mechanotransduction in the bone to determine the impact on RANKL and OPG. [61]  
  Following long-term SclAb treatment, bone formation begins to attenuate or decrease, 
suggesting a period where the bone begins to self-regulate the anabolic action. [38, 52, 57-59] It has 
been proposed that the dampening effects following long-term SclAb treatment may be due to a large 
and acute upregulation in inhibitory regulators of bone formation (SOST, DKK1).[37] We observed a 
similar upregulation of SOST and DKK1 with SclAb treatment. This compensatory response has been 
documented in the acute phase of treatment with significant upregulation observed following a single 
dose of SclAb. [37] Because SclAb acts to prevent the interaction of sclerostin with LRP5/6, not by 
blocking the production of sclerostin, it has been suggested that a signaling event may occur to increase 
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secretion of sclerostin following the initial blocking of LRP5 binding. [62] This event may lead to an 
increase in inhibitory regulators leading to the observed compensatory upregulation in SOST and DKK1 
we observed in order to regulate the concurrent early bone-formation gains.   
  While SclAb elicited increases in osteoblast and osteoblast progenitor markers and increases in 
inhibitory regulators in our OI tissue, the magnitude of this response varied across samples. Variability 
in treatment response has been observed clinically with no clear causation documented and no metric to 
predict which patients will positively respond to a therapy and which patient will require a completely 
different treatment approach to mitigate the effects of the disease. OI type, phenotypic severity and age 
provide valuable guides when determining a treatment plan but identification of factors that contribute to 
differential treatment response would be advantageous. For example, following two years of 
Pamidronate treatment in children with Type III and Type IV OI, Zacharin et al. reported no statistical 
correlation in age, phenotypic severity, or predicted collagen mutation on treatment response.[24] While 
nearly all patients in the study demonstrated improvements in BMD, magnitude of BMD gains differed 
between and within patients of the same OI type. We demonstrated that SclAb response statistically 
differed between OI Type (III, IV, III/IV) in key inhibitory genes (SOST, DKK1, TWIST1) and for 
osteoblast markers (RUNX2). Specifically, patients with OI Type III, considered the most severe form of 
children who survive through the neonatal period, demonstrated the greatest upregulation in these 
markers with treatment. It is understood that severity of the disease can vary within OI type. When 
treatment response was evaluated between individual patients, the magnitude of response differed within 
patients of the same OI classification suggesting factors beyond phenotype may be responsible for 
differential treatment response.  
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  When normalized to the average non-OI untreated control, we observed a differential expression 
in all genes evaluated among the seven OI samples. This variability in the untreated condition was 
present irrespective of OI type or bone origin. Interestingly, when OI tissue was treated with SclAb, 
untreated expression of bone formation markers appeared to impact the magnitude of response during 
our short-term treatment in vitro. Bone with the lowest relative untreated expression of osteoblast and 
osteoblast precursor markers SP7, RUNX2, COL1A1 and BGLAP were particularly impacted 
demonstrating the greatest upregulation following treatment. In contrast, samples with a high relative 
untreated expression of these markers, indicative of a bone forming response, were only moderately 
upregulated when treated with SclAb. From our results, we postulate that there is an upper limit for 
eliciting an early/rapid bone response with SclAb which is perhaps attributable to 1) the amount of 
available mesenchymal stem cells (MSCs) and quiescent bone lining cells [57, 63, 64] and 2) the 
available bone surface area for which osteoblasts can differentiate. We can reason that bone sites with 
high expression levels of osteoblast markers and osteoblast progenitors have “little room” for further 
formation where further minimal upregulation was observed. Second, there is a finite bone surface area 
in which SclAb can induce bone formation (without the use of co-treatment of bisphosphonate, for 
example [65, 66] and perhaps a maximization of bone forming surfaces in the sample had already 
occurred, further limiting bone response. Future work should evaluate these potential factors, including 
evaluating bone turnover markers (P1NP, TNSAP) and their role in determining the magnitude of 
treatment response. To decrease site-specific variability in samples, future studies should attempt to 
standardize bone harvest site, such as obtaining specimens from iliac crest biopsies.  While these 
locations may have a distinctly different mechanical loading environment than sites sampled here, they 
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represent a sampling area that has previously been used to characterize OI phenotype through 
histomorphometric assessment {Rauch, 2000 #68}. 
  The in vitro environment provides a safe and reductionist method to evaluate human tissue 
response to SclAb but the environment is limited in both biokinetic and metabolic factors inherent to the 
in vivo environment. We extended treatment to human bone from three OI patients in vivo using a 
xenograft model to evaluate the bone forming response to SclAb in an environment that more closely 
recapitulates the patient environment. [42] We implanted both cortical-derived (OI3 and OI6) and 
trabecular-derived tissue (OI4) and observed a greater magnitude of response to SclAb in trabecular-
derived implants following two weeks of treatment in both µCT and histomorphometry outcomes. For 
OI4, trabecular-derived implants, this response appeared to attenuate following four weeks of treatment 
where µCT changes measured from pre- to post- treatment decreased in magnitude compared to the two 
week treated implants from the same patient. Because of the limited bone tissue we received from 
patients OI3 and OI6, we did not allocate tissue to the four week treated time point (instead, using the 
tissue for in vitro analysis), so we did not evaluate treatment response in the cortical implants at four 
weeks. Our first description using this xenograft  demonstrated that cortical-derived bone with minimal 
human marrow cells at the time of implantation requires longer implantation duration to elicit a bone-
forming response and that trabecular derived- implanted patient tissue demonstrates a greater magnitude 
of response.[42] When the parallel cortical-derived bone tissue from OI3 and OI6 were treated acutely in 
vitro, we did observe an upregulation in osteoblast markers (particularly SP7) and an upregulation 
(compensatory response) in inhibitory regulators SOST and DKK1 indicating a treatment response. 
Future analysis using the proposed xenograft model should evaluate gene expression response analogous 
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to the panel reported in the present study to determine the effects of SclAb in the host-derived 
microenvironment in comparison to the in vitro response.  
Limitations 
There are several limitations to this study. We evaluated expression levels in OI patient bone 
tissue removed during corrective orthopaedic procedure using qPCR to quantify a panel of key genes 
involved in bone metabolism. We are therefore evaluating a specific point in time for these patients; it is 
both feasible and likely that expression levels will continue to change with growth and in consequence 
to environmental factors in this pediatric population. In addition, and because of the rarity of the disease 
and tissue, we took bone from patients who were pre, peri, and post-pubescent. We therefore likely 
captured bone when it was undergoing a cellular range of modeling to remodeling, adding to the 
complexity of the study.  However, these same challenges are representative of the challenges faced by 
treating physicians of patients with OI across age span. We were unable to standardize bone harvest site 
in the present study; instead, this rare pediatric bone tissue was taken as surgical waste from patients 
undergoing corrective orthopaedic procedure. Given this, we likely selected for more severe patients, as 
well as more severe sites, and were unable to compare to patients or anatomic sites not needing 
immediate surgical or medical attention. As indication for surgery varied across patients, so did the site 
of bone harvest. We did consider bone morphological type (trabecular- or cortical-derived) in our 
evaluation of treatment response. As such, it is feasible that expression levels varied by bone site within 
the same patient and site variation likely played a role in the untreated expression levels observed 
between OI patients and the magnitude of treatment response. Even so we believe this variation was not 
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a critical factor when evaluating treatment response within the patient where treatment response was 
normalized to that patient’s untreated gene expression in samples harvested from the same site. 
Furthermore, we recruited all OI patients which qualified for the study and did not differentiate findings 
based on sex. Differences in expression levels could exist between male and female patients. Regarding 
response to treatment, unpublished work in our lab has determined that magnitude of response to SclAb 
does not differ between sex in the Brtl/- murine model. The amount of nucleic acid concentration, which 
was dependent on the amount of bone tissue harvested, limited the number of genes we were able to 
evaluate using TaqMan qPCR in some patients. This also inhibited the number of conditions we were 
able to evaluate; as such future studies should include a baseline or “time 0” condition where bone 
removed from the patient is immediately processed for qPCR. This should also be performed because 
the act of culturing the bone itself may have altered gene expression; culture lacks all the growth factors 
inherent to in vivo and therefore may have influenced untreated expression. While our focus was on an 
abbreviated panel of genes (a key panel we identified from prior pre-clinical work using SclAb), future 
studies should build on this work through RNA-sequencing (RNA-seq) of the treated rare OI tissue. 
RNA-seq provides more data overall and makes it possible to detect previously unknown transcripts, 
isoforms, junctions and evaluate genes in pathways where the user has little baseline knowledge on 
location that may be implicated by treatment. [67, 68]  
Conclusions 
Using solid tissue isolates from human OI bone patients in vitro, SclAb activates downstream 
Wnt targets of WISP1 and TWIST1 and induces a compensatory response in SOST and DKK1 expression, 
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consistent with pre-clinical studies of ovariectomized rats and SOST and DKK1 in female Balb/c mice. 
In all samples, a bone-forming response to treatment was observed but the magnitude of this response 
was variable. While OI type and bone origin (cortical, trabecular) were influential in response, the level 
of untreated gene expression appeared to greatly influence the magnitude of response to SclAb in native 
human OI bone tissue. Clinical heterogeneity is a hallmark of OI; understanding a patient’s genetic, 
cellular and morphological bone phenotype may play an important role in predicting treatment response 
and could help guide clinical decision making. 
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Table 1. Patient demographics and bone sample type. 
 
 
*Color-coded by bone sample type; colors correspond to bar colors in Figure 3 and 4. **Color coded 
by OI Sillence Type classification; colors correspond to bar colors in Supplemental Figure 1 and 2.  














OI 1 Trabecular Revision Depo-testosterone
L 
Ulna/Radius 17/M Wheelchair; small stature III 13
OI 2 Cortical Osteotomy None R Tibia/Fibia 21/M Wheelchair; small stature III 10
OI 3 Cortical Bilateral Osteotomies None R & L Femur 16 mos/F
Walks w/o assistance; 
normal stature III/IV 5
OI 4 Trabecular Osteoplasty & Nail Placement
Ca Citrate-
Vitamin D3 R Femur 23/F
Walks w/o assistance; 
normal stature III/IV 7
OI 5 Trabecular Fracture None R Femur 16/M Walks w/ periodic wheelchair use; normal stature III/IV 14
OI 6 Cortical Fracture None R Femur 2/F Walks w/o assistance; normal stature III/IV 7







Mean: 12 yrs; 
Range: 10-15 
yrs; F=2, M=3
Normal gait prior to injury Unaffected Total: 51
Average Non-OI Patients (N=5)
OI Patients
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Figure 1. A. Cortical and trabecular bone samples (~2 mm3 size per sample with each patient yielding 
up to 14 usable bone fragments) from osteogenesis imperfecta (OI) patients and morselized trabecular 
bone samples from non-OI control patients typically discarded as surgical waste during corrective 
orthopaedic procedures were collected to media and randomly assigned: untreated (UN), low-dose 
SclAb (TRL, 2.5 µg/mL), or high-dose SclAb (TRH, 25 µg/mL) group and maintained in culture (37ºC). 
Group assignment was as such that each group contained equal number of samples depending on patient 
yield with each 6 well plate generally containing between 2-3 ~2mm3 bone fragments. Treatment 
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occurred on day 2 and 4 and samples were removed on day 5 for RNA extraction. One bone sample per 
patient was formalin-fixed upon harvest for baseline hematoxylin and eosin (H&E). B. A subset of OI 
bone tissue (14 samples from 3 OI patients) was immediately implanted subcutaneously on the dorsal 
surface (~2 mm3 in size) of an athymic mouse representing our xenograft model. Implanted mice were 
randomly assigned to an UN or high dose (TRH, 25 mg/kg) group for 2 or 4 weeks where SclAb 
treatment was administered via subcutaneous injection 2 times a week. All mice received calcein and 
alizarin fluorochrome injections 7 and 1 day prior to sacrifice, respectively. Mice were imaged via µCT 
24 hours after implantation and immediately following sacrifice. Following imaging, implanted OI bone 
tissue was removed from the host and plastic processed for dynamic histomorphometry analysis. Patient 
radiograph provided by MSC. 
  





Figure 2. Patient donor bone tissue morphology for OI and non-OI patients were evaluated using 
hematoxylin and eosin (H&E). One bone sample per patient was not placed in culture but immediately 
formalin fixed, paraffin embedded and stained with H&E. For the OI patients, tissue ranged from 
cortical (OI2, OI3, OI6) and trabecular (OI1, OI4, OI5, OI7) bone tissue. In all cases, non-OI control 
bone tissue (bottom) was morselized trabecular bone due to the method it was removed during anterior 
cruciate ligament (ACL) reconstruction tibial tunnel placement (non-OI 1-5). Colored boxes surrounding 
OI patient samples correspond to subsequent figures depicting fold-change gene expression. Samples 
depicted are representative of bone samples used in the in-vitro assay. Images were acquired at 20x. 
Scale bar= 500 µm. 
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Figure 3. Quantification of fold-differences in the untreated expression of 10 genes of interest for each 
OI patient (n=7) normalized to the average untreated non-OI control patients (n=5) corrected by HPRT1. 
Height of bars represents fold-change derived from mean technical replicates and error bars represent 
standard error of the mean (SEM) derived from technical replicates of up to three pooled bone samples 
for the untreated condition for each OI patient. Untreated non-OI (black bar) is the average of these data 
from 5 patients. OI patients are organized by cortical-like bone samples (right, blue) and trabecular-like 
bone samples (left, green). [*] and brackets denote significant differences in OI expression compared to 
untreated controls at p≤0.05. Missing data due to insufficient nucleic acid content (NA) is indicated. 
UN= untreated; CORT=cortical- like samples; TRAB=trabecular- like samples.  
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Figure 4. Quantification of fold-change expression of 10 genes of interest due to low (TRL) and high 
(TRH) dose SclAb treatment in vitro. Each OI patient’s treated conditions were normalized to the 
individual patient’s untreated condition, corrected by HPRT1. Height of bars represents relative fold-
change derived from mean technical replicates and error bars represent standard error of the means 
(SEM) from technical replicates of up to three pooled bone samples for each condition (UN, TRL, TRH) 
for each OI patient (n=7). Data is organized by cortical-like patient samples (right, blue; OI2, OI3, OI6) 
and trabecular-like patient samples (left, green; OI1, OI4, OI5, OI7). [*] and brackets denote 
significance within each patient due to treatment at p ≤ 0.05. Missing data due to insufficient nucleic 
acid (NA) content is indicated. UN=untreated; TRL=low dose treatment; TRH=high dose treatment; 
CORT=cortical-like samples; TRAB=trabecular- like samples. 
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Figure 5. SclAb treated fold change for 10 genes of interest plotted against the individual patient’s 
untreated fold change by dose (treated low dose, TRL; treated high dose, TRH). In particular, magnitude 
of treatment response of osteoblast markers and precursors COL1A1, RUNX2, SP7 and BGLAP appeared 
to be impacted by the OI patient’s relative untreated expression of the osteoblast related genes. SclAb 
treated OI patient bone that demonstrated a large magnitude of upregulation generally presented with 
low untreated expression. Conversely, patient bone that demonstrated little to no upregulation in 
osteoblast markers with SclAb treatment change due to treatment generally demonstrated high relative 
untreated expression of the gene of interest. Data represents treatment fold-change relative to the 
individual patient’s untreated condition (Y-axis) plotted against the individual patient’s untreated fold-
change relative to the average non-OI control patients (X-axis). Specifically, each data point on the Y-
axis represents individual OI-patient SclAb treated bone sample (TRL=red stars; TRH=grey diamonds) 
fold-change derived from technical replicates of three pooled condition bone samples normalized to the 
individual patient’s untreated condition. X-axis is the individual patient’s untreated fold-change 
condition normalized to the average non-OI untreated controls. TRL=treated low dose; TRH=treated 
high dose; UN=untreated; ave=average.  
  




Figure 6. Due to the amount of patient bone procured, additional cortical-derived bone tissue from 
patient OI3 and OI6 and trabecular-derived bone tissue from patient OI4 were implanted subcutaneously 
into an athymic mouse representing our xenograft model system. A. OI implants treated with SclAb 
demonstrated increases in bone surface (BS) measured as a percent change from pre- to post- in vivo 
µCT following two weeks compared to untreated OI implants. B. Histomorphometry corroborated 
treatment-induced increases in BS at two weeks (bottom panel) demonstrating robust calcein (green) and 
alizarin (red) fluorochrome labeling (white arrows) compared to the untreated two week implants which 
had minimal non-specific calcein labeling only (yellow arrow). Fluorescent images acquired at 20x. 
Scale bar= 100 µm.   




Supplemental Figure 1. Average fold-change expression of 10 genes of interest due to low (TRL) and 
high (TRH) dose SclAb treatment by patient’s OI Sillence type clinical classification. Multiple bone 
tissue samples were harvested from patients clinically classified by physical examination and genetic 
testing as either Type III (n=2), Type III/IV (n=4) or Type IV (n=1). Average treated conditions for each 
OI type were normalized to average untreated condition for that OI type, corrected by HPRT1. For 
example, average TRL for all OI Type III patients were normalized to the average OI Type III untreated 
(UN) condition. Height of bars represents relative fold-change derived from combined mean technical 
replicates for all patients of that OI Type (each patient’s technical replicates were averaged over 
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condition) and error bars represent standard error of the means (SEM) from averaged technical replicates 
which were derived from three pooled bone samples for each condition (UN, TRL, TRH) for each OI 
patient combined by OI type. Horizontal dotted line represents 1, or the normalized untreated condition 
and average treatment response (TRL and TRH) are plotted. Black circles represent individual OI 
patient fold change for each condition and correspond to results presented in Figure 4. Black circles 
indicate variability in treatment response to acute SclAb present within bone tissue obtained from 
patients of the same clinical OI classification. No significance was observed between UN, TRL and 
TRH conditions within OI type but difference in magnitude of treatment response by either increase or 
decrease in mean fold change gene expression can be appreciated between OI type. 
  





Supplemental Figure 2. A. Two-way non-repeated measures ANOVA results for each gene of interest 
comparing average treatment condition (UN, TRL, TRH) within OI type (Type III, Type III/IV, Type 
IV) normalized to average non-OI untreated control condition. Treatment and patient type served as 
factors and table values are bolded when significance was reached. B. Quantification of fold-change 
expression levels of 10 genes of interest for average OI Type III, average OI Type III/IV, and average 
OI Type IV patients in their untreated (UN) and SclAb treated low (TRL) and high (TRH) conditions. 
The average OI patient conditions were normalized to the average non-OI untreated condition, corrected 
by HPRT1, in order to create a common scale for the three OI patient populations. Height of bars 
represents relative fold-change derived from the average of each patients conditional (UN, TRL, TRH) 
mean technical replicates and error bars represent standard error of the means (SEM) from these 
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technical replicates of three pooled bone samples from each condition, for each patient. Data is 
organized by OI Type III patients (left, horizontal stripes) and OI Type IV patients (right, diagonal 
stripes). [*] and brackets denote significant difference from the non-OI untreated control using a 
Dunnett’s post-hoc test at p ≤ 0.05.   
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